Alglucosidase Alfa: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Alglucosidase Alfa. Educational only — not medical advice.
Labeled uses
LUMIZYME® is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (acid α-glucosidase [GAA] deficiency).
Source: FDA labeling via NIH DailyMed (set d6bfbc45…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.